Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease.

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease. Abstract Text:

N A Afzal,A Ozzard,S Keady,M Thomson,S Murch,R Heuschkel,N A Afzal,A Ozzard,S Keady,M Thomson,S Murch,R Heuschkel,N A Afzal,A Ozzard,S Keady,M Thomson,S Murch,R Heuschkel,

The aim of this study was to review the impact of infliximab therapy on children with treatment-resistant Crohn's disease. Treatment resistance was defined as clinically active disease despite > 4 months of immunosuppressive therapy. The outcome variables were time to first remission, duration of remission and the need for surgery. 24 children received 90 infusions of infliximab (16 boys; median 10.3y, range 1.0-14.4y); all had three infusions as an induction course. 17 (70.8%) achieved clinical remission, with 14/17 (82.3%) relapsing within 4 months of the third infusion. 6/7 in the non-responding group and 8/17 of the responders required surgery with an insignificant difference in the median time to surgery (p = 0.49). Four remain dependent on regular infliximab. Infliximab is well-tolerated and highly effective in achieving clinical remission in children with refractory Crohn's disease but may only delay and not avoid the need for surgery. Failure to achieve clinical remission by the 3rd infusion significantly increases the risk of surgery.

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease. Publishing Authors By Initials

NA Afzal,A Ozzard,S Keady,M Thomson,S Murch,R Heuschkel,NA Afzal,A Ozzard,S Keady,M Thomson,S Murch,R Heuschkel,NA Afzal,A Ozzard,S Keady,M Thomson,S Murch,R Heuschkel,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Digestive diseases and sciences

VOLUME: 52

Page Numbers: 3329-33

Journal Abbreviation: Dig. Dis. Sci.

ISSN: 0163-2116

DAY: 5

MONTH: 09

YEAR: 2007

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7902782

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease.

AFFILIATION: Department of Paediatrics, Southampton University Hospital NHS Trust, Southampton.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Dig Dis Sci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease Related Publications

• Inflammatory bowel disease in children.
• Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric crohn' disease.